Key result
Continuation of anti-platelet therapy until coronary artery bypass grafting significantly increased excessive postoperative bleeding compared to preoperative discontinuation (59% vs. 33%, p=0.02), and preoperative point-of-care platelet function testing was a strong predictor of this bleeding risk.
Why the study?
Does point-of-care platelet function testing predict excessive bleeding and transfusion requirements in patients undergoing coronary artery bypass grafting?
Population
84 patients undergoing isolated coronary artery bypass grafting. Group A were on anti-platelet therapy until…
Design
Cohort
Follow-up
In-hospital (perioperative period)
Authors
Loading...
May support preoperative antiplatelet discontinuation before CABG; leaves open the utility of routine platelet function testing.
Cohort (n=84)
Double-blind
No
Does point-of-care platelet function testing predict excessive bleeding and transfusion requirements in patients undergoing coronary artery bypass grafting?
Absolute Event Rate: 59% vs 33%
p-value: p=0.02
Peri-operative point-of-care platelet function testing using the Multiplate device strongly predicts bleeding and transfusion requirements in CABG patients who remain on anti-platelet therapy until surgery.
Mishra et al. (2015) conducted a cohort in Coronary artery disease requiring coronary artery bypass grafting (n=84). Continuation of anti-platelet therapy until surgery vs. Discontinuation of anti-platelet therapy ≥5 days preoperatively was evaluated on Excessive bleeding (>2.5 ml/kg/h) within first 3 h postoperative (p=0.02). Continuation of anti-platelet therapy until coronary artery bypass grafting significantly increased excessive postoperative bleeding compared to preoperative discontinuation (59% vs. 33%, p=0.02), and preoperative point-of-care platelet function testing was a strong predictor of this bleeding risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: